Efficacy and Safety of First-Line Therapies in
            <i>EGFR</i>
            -Mutated Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Haeussler, Katrin; Wang, Xuan; Winfree, Katherine B.; D’yachkova, Yulia; Traore, Sory Ibrahima; Puri, Tarun; Thom, Howard; Papagiannopoulos, Christos; Nassim, Maria; Taipale, Kaisa

doi:10.2217/fon-2021-0885

Cited by 6 publications

(4 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this was not fully corroborated when used in combination with pemetrexed/carboplatin therapy [ 10 , 14 , 18 , 22 ]. Interestingly, the recent network meta-analysis by Haeussler and colleagues in 2022 assessed the comparative effectiveness and safety profiles for multiple first-line treatment options indicated for advanced EGFR mutation-positive NSCLC clinical cases [ 25 ]. This investigation performed a Bayesian network meta-analysis across multiple first-line treatments in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all comparative analyses [ 25 ].…”

Section: Reviewmentioning

confidence: 99%

“…Interestingly, the recent network meta-analysis by Haeussler and colleagues in 2022 assessed the comparative effectiveness and safety profiles for multiple first-line treatment options indicated for advanced EGFR mutation-positive NSCLC clinical cases [ 25 ]. This investigation performed a Bayesian network meta-analysis across multiple first-line treatments in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all comparative analyses [ 25 ]. This study's dataset outcomes highlighted that other therapeutic combination, such as ramucirumab/erlotinib, was more effective and had an enhanced safety profile compared to the gefitinib/erlotinib therapeutic regime [ 25 ].…”

Section: Reviewmentioning

confidence: 99%

“…This investigation performed a Bayesian network meta-analysis across multiple first-line treatments in such clinical cases, with gefitinib/erlotinib being the baseline reference therapy for all comparative analyses [ 25 ]. This study's dataset outcomes highlighted that other therapeutic combination, such as ramucirumab/erlotinib, was more effective and had an enhanced safety profile compared to the gefitinib/erlotinib therapeutic regime [ 25 ].…”

Section: Reviewmentioning

confidence: 99%

See 2 more Smart Citations

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Kanagalingam¹,

Haq²,

Srinivasan³

et al. 2023

Cureus

View full text Add to dashboard Cite

Current non-small cell lung cancer (NSCLC) treatment consists of various combinations of surgery, chemotherapy, and/or radiation, depending on the tumor stage. Individuals with stage II-IIIa NSCLC undergo surgery, followed by combination chemotherapy containing cisplatin, such as vinorelbine + cisplatin. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib, act by inhibiting any signaling pathway containing the EGFR mutation and inhibiting the growth of NSCLC. TKI is a treatment option in advanced NSCLC, resulting in more prolonged progression-free survival (PFS). This manuscript aims to evaluate the influence of utilizing gefitinib -either alone or in combination with conventional chemotherapeutic drug regimens upon NSCLC patient profile survival parameters. A systematic literature review was conducted across multiple scientific literature repositories. The review was performed using the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020.There were six randomized clinical trials (RCT) and five retrospective studies. The overall consensus based on the end outcome of each published journal on the effectiveness of gefitinib as a treatment option for NSCLC indicated that there was a notable difference in overall survival (OS) and progression-free survival (PFS) and disease-free survival (DFS) datasets. Gefitinib use correlated with increased timeframes for multiple patient survival parameters within articles shortlisted in this investigation. However, more comprehensive investigations are required to validate such correlations. Gefitinib did demonstrate the potential to provide beneficial effects and counteract NSCLC within such patients.

show abstract

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Kanagalingam¹,

Haq²,

Srinivasan³

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in NSCLC cells (2) . However, the relatively rapid emergence of resistance to erlotinib monotherapy substantially limits overall therapeutic benefit (3,4) .…”

Section: Introductionmentioning

confidence: 99%

Synergistic Effects of 2-Deoxy-D-Glucose and Cinnamic Acid with Erlotinib on NSCLC Cell Line

Al-khfajy,

Munaf Hashim Abdulrazzaq,

Al-Mashhadani

2023

IJPS

View full text Add to dashboard Cite

Background: In spite of all efforts, Non-small cell lung cancer (NSCLC) is a fatal solid tumor with a poor prognosis as of its high metastasis and resistance to present treatments. Tyrosine kinase inhibitors (TKI) such as erlotinib are efficient in treating NSCLC but the emergence of chemoresistance and adverse effects substantially limits their single use. Objective: in this study, the combination treatments of either 2-deoxy-D-glucose (2DG) or cinnamic acid (CINN) with erlotinib (ERL) were tested for their possible synergistic effect on the proliferation and migration capacity of NSCLC cells. Methods: In this study, NSCLC model cell line A549 was used to investigate the effects of single compounds and their combination on cell growth inhibition, clonogenic potential, and migration capacity. Next, the Combination index (CI) and the Dose-Reduction Index (DRI) were determined to determine the nature of the drug’s combination and to measure how many folds the dose could be lowered for each drug in a synergistic combination. Results: the combination treatment demonstrated more significant inhibition of viability of A549 cells compared to individual therapy. Our data show that CINN augments the sensitivity to erlotinib in all doses tested. The combination of 2DG or CINN with erlotinib also reduced the clonogenicity of NSCLC cells up to 67% and 85%, respectively, as compared to the erlotinib single treatment. Furthermore, CINN +ERL decreased the migratory ability of A549 cells by 3-fold and further induced much more apoptotic cell death phenotypes. Conclusion: in summary, co-administration of 2DG or cinnamic acid with erlotinib increases the inhibitory effects of erlotinib on NSCLC cell tumorigenicity and migration.

show abstract

Ocular surface toxicities associated with modern anticancer therapies

Boucher,

Haigh,

Barreau

et al. 2024

Survey of Ophthalmology

View full text Add to dashboard Cite

Efficacy and Safety of First-Line Therapies in EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis

Cited by 6 publications

References 81 publications

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Comparing Gefitinib and Traditional Chemotherapy for Better Survival in Patients With Non-Small Cell Lung Cancer: A Systematic Review

Synergistic Effects of 2-Deoxy-D-Glucose and Cinnamic Acid with Erlotinib on NSCLC Cell Line

Ocular surface toxicities associated with modern anticancer therapies

Contact Info

Product

Resources

About